Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to test the hypothesis that LY450139 given orally will slow the decline associated with AD as compared with placebo. This will be evaluated sometime between 64 and 88 weeks after initiation of treatment; the precise timing is specified in an Ethical Review Board (ERB) supplement to this protocol.
Critère d'inclusion
- Alzheimers Disease